Vernakalant Versus Flecainide: Atrial Contractility

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status and phase

Unknown
Phase 4

Conditions

Atrial Fibrillation

Treatments

Drug: Flecainide
Drug: Vernakalant

Study type

Interventional

Funder types

Other

Identifiers

NCT01646281
NL39854.068.12

Details and patient eligibility

About

Atrial fibrillation (AF) is associated with decreased atrial contractility which is associated with stroke. Decreased contractility becomes apparent after cardioversion of atrial fibrillation, a short period (weeks) during which stroke risk is increased. Improved contractility immediately after cardioversion may prevent arrhythmia progression. In addition, it may reduce the stroke risk. Vernakalant is a new antiarrhythmic drug able to convert atrial fibrillation to sinus rhythm and at the same time increase atrial contractility. The latter has not yet been shown in humans and is subject of the present investigation. Our hypothesis is that in humans the contractility of the atria is higher after administration of vernakalant compared to flecainide. If indeed vernakalant improves atrial contractility after cardioversion further studies into the effect on long-term arrhythmia progression and stroke prevention may follow.

Enrollment

70 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • persistent AF or paroxysmal AF
  • eligible for treatment with vernakalant or flecainide infusion to restore sinus rhythm
  • receiving adequate anticoagulant therapy (or having an episode of AF lasting < 24 hours)

Exclusion criteria

  • refusal or inability to give informed consent to participate in this study
  • atrial flutter
  • contra-indications for receiving vernakalant or flecainide according to MUMC+ protocol (unstable hemodynamic condition, LVEF < 40%, inadequate potassium levels, acute ischaemia, sinus node dysfunction)
  • age < 18 years

Trial design

70 participants in 2 patient groups

Flecainide
Active Comparator group
Description:
Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
Treatment:
Drug: Flecainide
Vernakalant
Active Comparator group
Description:
Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
Treatment:
Drug: Vernakalant

Trial contacts and locations

0

Loading...

Central trial contact

Ione Limantoro, MD; Harry Crijns, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems